Feature

UK Authorization for Aflibercept  

MHRA clears Eylea for macular edema following retinal vein occlusion

  • By

  • March 3, 2026

  • 2 min

Share

The UK's MHRA has approved aflibercept 8 mg (Eylea®) for treating visual impairment caused by retinal vein occlusion (RVO). This marks the third approval for the higher-dose formulation, supported by data from the Phase III QUASAR trial where aflibercept 8 mg demonstrated comparable visual acuity gains to the 2 mg dosage with fewer injections needed. By week 64, over 60% of patients in the 8 mg group had longer treatment intervals, indicating a significant reduction in treatment burden while achieving similar anatomical outcomes and maintaining a consistent safety profile.

Original Source(s)

UK Authorization for Aflibercept  

MHRA clears Eylea for macular edema following retinal vein occlusion

  • March 3, 2026

  • 2 min

Related Content

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

Understanding Protocol AO, the DRCR Retina Network’s Study of Home OCT

A conversation with Christina Y. Weng, MD, MBA

Efficacy and Safety of 8 mg Aflibercept in PULSAR Extension

Patients who switched from 2 mg to 8 mg maintained their vision and extended time between treatments with no vasculitis or other retinal occlusive events.